18 August 2017Americas

Mylan finalises $465m settlement with US government

Mylan has finalised a $465 million payment to the US government to settle a lawsuit about the classification of EpiPen Auto-Injector (epinephrine) under the Medicaid Drug Rebate Program.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

FDA grants Teva approval for first EpiPen generic

17 August 2018 The US Food and Drug Administration yesterday granted Teva approval for the first generic version of EpiPen, an autoinjector pen used for the emergency treatment of allergic reactions.

Americas

Mylan to pay US government $465m over EpiPen

11 October 2016 Mylan has agreed to pay the US Department of Justice and other government agencies $465 million to settle questions about the classification of EpiPen Auto-Injector under the Medicaid Drug Rebate Program.

More on this story

Americas

FDA grants Teva approval for first EpiPen generic

17 August 2018 The US Food and Drug Administration yesterday granted Teva approval for the first generic version of EpiPen, an autoinjector pen used for the emergency treatment of allergic reactions.

Americas

Mylan to pay US government $465m over EpiPen

More on this story

Americas

FDA grants Teva approval for first EpiPen generic

17 August 2018 The US Food and Drug Administration yesterday granted Teva approval for the first generic version of EpiPen, an autoinjector pen used for the emergency treatment of allergic reactions.

Americas

Mylan to pay US government $465m over EpiPen